Will Natco and Dr. Reddy’s bet on weight-loss drug Ozempic’s copy pay off?
In the face of looming revenue decline from blood cancer medication Revlimid, Indian pharma companies Natco Pharma and Dr. Reddy’s Laboratories are shifting their focus to a promising new frontier: a weight loss drug modelled after Ozempic. This strategic pivot aims to stabilise their growth and set them on a path toward recovery in an
Will Natco and Dr. Reddy’s bet on weight-loss drug Ozempic’s copy pay off? Read More »